Moderna (MRNA) has seen a mix of positive and negative news recently. Despite the volatility, developing trends seem to be pointing towards an uncertain future for the company. With the negative indicators of top FDA officials resigning and causing a hit to their vaccines stocks, and the
USPTO ruling some of Moderna's key mRNA patents unpatentable, the outlook seems challenging. On the other hand, they have been awarded $590 million from HHS for continued mRNA vaccine development against pandemic flu threats. The company is also reportedly advancing in trials for a novel norovirus vaccine, taking a large step forward in mRNA solid tumour vaccines, and prepping for a mRNA fight against a rising bird flu threat.
Earnings reports reveal reduced COVID vaccine sales, but higher than expected overall vaccine sales. Innovation continues with the development of new mRNA therapies, but investor sentiment dips due to growing vaccine skepticism and RFK Jr.'s anti-vax views. While some rumors speculate whether Moderna could be a potential 'buy' at the current market drops, it is advised that potential investors take into account the above turbulence as the company progresses.
Moderna MRNA News Analytics from Wed, 12 Jun 2024 07:00:00 GMT to Sat, 05 Apr 2025 23:04:04 GMT -
Rating -2
- Innovation 6
- Information 7
- Rumor -6
